New personalized cancer vaccine shows promise in early trial
NCT ID NCT06631079
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a personalized oral DNA cancer vaccine (NECVAX-NEO1) given alongside standard immunotherapy drugs in 20 adults with solid tumors. The vaccine is designed to target unique markers on each patient's cancer. The study aims to check safety and whether the combination can help control tumor growth. Participants must already be on immunotherapy and have stable or responding disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Personalized oral DNA cancer vaccine (NECVAX-NEO1) plus standard immunotherapy (PD-1/PD-L1 inhibitors)
What this could lead to
If successful, this could offer a new way to boost the immune system's ability to fight solid tumors, potentially improving tumor control when combined with standard immunotherapy.
What could go wrong
This is an early-phase trial with only 20 participants, so results may not apply to all patients. The vaccine is personalized, which is complex and may not work for everyone. Side effects from the combination therapy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHUS Santiago de Compostela
Santiago de Compostela, Spain
-
Charité
Berlin, Germany
-
Comprehensive Cancer Center
Munich, Germany
-
Fundacion Jimenez Diaz
Madrid, Spain
-
Institut Catala d'Oncologia
Barcelona, Spain
-
NCT
Heidelberg, Germany
-
National Cancer Center
Vilnius, Lithuania
-
Vall d'Hebron
Barcelona, Spain